Here are the five companies, what they do, and when GV invested:
Spero Therapeutics, a biopharmaceutical company creating treatments for bacterial infections, started trading on the Nasdaq last fall and has a current market cap of $204.8 million.
GV led its Series C in March 2017 and its stake is now worth $15.79 million, according to FactSet.
Arsanis, which is working on antibody immunotherapies for infectious diseases, went public in November of last year and has a market cap of $327.2 million. GV invested in its Series D in April 2017 and its stake is worth $10.62 million, according to FactSet.
Arcus Bioscience, which develops cancer immunotherapies, went public in March and has a market cap of $657 million.
GV first invested in Arcus' Series B in 2016 and again in its Series C in 2017, and its stake is worth $80.9 million, according to FactSet.
ARMO Biosciences fights cancer through immunotherapy. It went public in January 2018 has a market cap of $1.1 billion. GV invested in its Series C as well as its Series C-1 in 2016 and 2017 respectively, and its stake is currently worth $45.14 million.
Denali Therapeutics creates therapies for neurodegenerative diseases like Alzheimer's and Parkinson's and went public in December 2017 and currently has a market cap of $1.86 billion.
There's a good chance 2018 will bring more excitement: Nasdaq's head of healthcare listings recently predicted that biotech M&A will be hot this year and that we could see 30+ total biotech IPOs.
GV portfolio company 23andMe is expected to file before the end of the year.